The Princeton, N.J., company will give one added share to stockholders of record as of the close of business Aug. 22. The new shares will be circulated Aug. 31.
Pharmasset currently has around 37.7 million shares outstanding, and that will double to 75.4 million following the split.
The company, which currently has no products on the market, lost $22.6 million, or 60 cents per share, in the three months ended June 30.
Hepatitis C drug developer Pharmasset Inc.(NASDAQ:VRUS) reported Tuesday that its board of directors approved a two-for-one split of the company's common stock.